Aniseikonia following intravitreal ranibizumab treatment for branch retinal vein occlusion
| Autor: | Fumiki Okamoto, Shohei Morikawa, Yoshimi Sugiura, Tomoya Murakami, Tetsuro Oshika, Takahiro Hiraoka |
|---|---|
| Rok vydání: | 2021 |
| Předmět: |
medicine.medical_specialty
Visual acuity genetic structures Visual Acuity Angiogenesis Inhibitors Ranibizumab Ophthalmology Retinal Vein Occlusion Aniseikonia medicine Humans Macropsia External limiting membrane Micropsia business.industry General Medicine medicine.disease eye diseases Treatment Outcome medicine.anatomical_structure Intravitreal Injections Branch retinal vein occlusion sense organs medicine.symptom Epiretinal membrane business Tomography Optical Coherence medicine.drug |
| Zdroj: | Japanese Journal of Ophthalmology. 65:672-679 |
| ISSN: | 1613-2246 0021-5155 |
| Popis: | To quantify aniseikonia following intravitreal ranibizumab (IVR) in patients with branch retinal vein occlusion (BRVO) and assess the relationship between aniseikonia and retinal microstructure. Prospective observational study. This study included 50 patients undergoing IVR treatment for unilateral BRVO. The degree of aniseikonia and best-corrected visual acuity (BCVA) was examined, and retinal microstructure was assessed with optical coherence tomography (OCT) before and 1, 2, 3, 4, 5, and 6 months after treatment. Based on OCT images, we assessed central retinal thickness (CRT), presence of the epiretinal membrane, and serous retinal detachment (SRD), as well as status of the external limiting membrane and ellipsoid zone. At baseline, mean aniseikonia was − 1.0 ± 2.5%, ranging from − 11.0 to + 6.0%. Nine out of 50 patients had micropsia (18%), one had macropsia (2%), and 40 had no aniseikonia (80%). After 6 months of treatment, mean aniseikonia was − 0.7 ± 1.5%, ranging from − 4.5 to + 3.5%. BCVA significantly improved after treatment (P |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full text from SpringerLink